Many people who face a heightened likelihood of heart disease and heart attacks can take protective measures, whether by adjusting their lifestyle or starting medication. But 1 in 5 people carry a risk factor that isn’t so easily addressed.
This gap in medicine is also a potentially massive market for drugmakers, which are advancing experimental treatments for the risk factor through late-stage trials, including front-runner Novartis.
Their target is what’s known as Lp(a) — or, as it’s commonly said, “L-P-little-A.” If you have high levels of Lp(a), it’s largely because of genetics, and there’s not much you can do about it.
STAT+ Exclusive Story
Already have an account? Log in
This article is exclusive to STAT+ subscribers
Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.
Already have an account? Log in
Individual plans
Group plans
To read the rest of this story subscribe to STAT+.